Aarti Drugs Limited — Others, 24-12-2024: Action(s) taken or orders passed

Aarti Drugs Limited has received the Establishment Inspection Report (EIR) from the US FDA, confirming the closure of its inspection at the API manufacturing facility in Tarapur, Maharashtra. The facility has been classified as “voluntary action indicated” (VAI), indicating minimal compliance with good manufacturing practices (CGMP). This positive outcome enables the company to resume exports of key products, including Ciprofloxacin HCl API and Zolpidem Tartrate API, to the US market. This development is likely to enhance investor sentiment, presenting a positive outlook as the company strengthens its market position without any immediate financial impacts.